Loading clinical trials...
Loading clinical trials...
Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease
Conditions
Interventions
pomalidomide
bortezomib
+2 more
Locations
5
United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
Boston University School of Medicine
Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
Duke University Medical Center
Durham, North Carolina, United States
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Start Date
March 1, 2013
Primary Completion Date
October 31, 2018
Completion Date
October 31, 2018
Last Updated
May 9, 2023
NCT03717844
NCT03499808
NCT00536601
NCT01533194
NCT00344526
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions